Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01397201
First received: July 18, 2011
Last updated: April 30, 2014
Last verified: April 2014
  Purpose

The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.), fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 220 mcg b.i.d. and placebo b.i.d. over an 8-week treatment period in asthmatic patients aged 12 to 65 years inadequately controlled on low dose Inhaled corticosteroid (ICS) as demonstrated by a decrease in forced expiratory volume in one second (FEV1 (range 10-25%) and an asthma control questionnaire (ACQ-6) greater or equal 1.5 at time of randomisation


Condition Intervention Phase
Asthma
Drug: Placebo
Drug: BI 54903
Drug: Fluticasone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA 220 mcg b.i.d. in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary endpoint will be the mean change from randomisation baseline to the end of the 8-week treatment period in trough (pre-dose and pre-rescue bronchodilator) forced expiratory volume in one second (FEV) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced vital capacity (FVC) after 2, 4 and 8-week treatment periods [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced expiratory volume in one second (FEV1) after 2 and 4-week treatment periods [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Weekly mean pre-dose (and pre-rescue) peak expiratory flow (PEF) as assessed via Asthma monitor (AM2+) in the morning and evening [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Weekly mean rescue medication use (daytime and night-time) as assessed via asthma monitor (AM2+) in the morning and evening [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Mean change from randomisation baseline in asthma control questionnaire (ACQ-6) scores at subsequent study visits [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Mean change from randomisation baseline in asthma quality of life questionnaire (AQLQ(S)+12) scores at subsequent study visits [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Time to withdrawal due to first asthma exacerbation [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Mean changes from randomisation baseline in trough (morning pre-dose and pre-rescue bronchodilator) FEF25-75 after 2, 4 and 8-week treatment periods [ Time Frame: week 2, 4 and 8 ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: July 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 54903 LD BID
patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
Drug: BI 54903
2 puffs b.i.d. BI54903 medium range via Respimat inhaler
Drug: Placebo
2 puffs b.i.d. placebo HFA MDI
Experimental: BI 54903 MD BID
patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
Drug: Placebo
2 puffs b.i.d. placebo HFA MDI
Drug: BI 54903
2 puffs b.i.d. BI54903 via Respimat inhaler
Experimental: BI 54903 HD BID
patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
Drug: BI 54903
2 puffs BI54903 via Respimat inhaler
Drug: Placebo
2 puffs b.i.d. placebo HFA MDI
Active Comparator: Fluticasone propionate 220mcg BID
patient to receive Fluticasone HFA MDI inhaler containing 220 mcg ICS plus placebo matching Respimat inhaler
Drug: Placebo
2 puffs b.i.d. placebo BI54903
Drug: Fluticasone
2 puffs b.i.d. 110mcg Fluticasone propionate HFA MDI
Placebo Comparator: Placebo
patient to receive placebo matching Respimat inhaler plus placebo matching HFA MDI inhaler
Drug: Placebo
2 puffs b.i.d. placebo HFA MDI
Drug: Placebo
2 puffs placebo BI54903 via Respimat inhaler

  Eligibility

Ages Eligible for Study:   12 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Must be willing and able to give informed consent
  2. Male and female patients aged at least 12 to 65 years
  3. All patients must have a history of asthma diagnosed by a physician for at least three months at the time of enrolment into the trial according to the 2009 Global Initiative for Asthma (GINA) Guidelines. The initial diagnosis of asthma must have been made before the age of 40 years
  4. All patients must be on a maintenance treatment with either medium-dose inhaled corticosteroid (ICS) plus long acting beta agonist (LABA) or high-dose inhaled corticosteroid (ICS) without long acting beta agonist (LABA), stable for at least six weeks prior to Visit 1
  5. All patients must have a pre-bronchodilator forced expiratory volume in one second (FEV1) of not less than 60 to 90% of predicted normal and an asthma control questionnaire (ACQ-6) mean score of less than 1.5 at the pre-screening Visit 1
  6. All patients must have an improvement in FEV1 not less than 12 % above baseline and an absolute change of at least 200 mL within 15-30 min after administration of 400 mcg salbutamol/albuterol hydrofluoroalkane metered dose inhaler (HFA MDI)
  7. Patients must be never-smokers or ex-smokers with a smoking history of less than 10 pack-years and smoking cessation at least one year prior to screening
  8. Patients must be able to use Respimat® inhaler and metered dose inhaler (MDI) correctly
  9. Patients must be able to perform all trial-related procedures including technically acceptable pulmonary function tests and electronic peak expiratory flow (PEF) measurements, and must be able to maintain records during the study period as required in the protocol
  10. To enter treatment period following additional criteria have to be met (at randomisation visit):

    • During the run-in period (at the same clinic visit) all patients must be both symptomatic (ACQ-6 mean score equal to or greater than 1.5) and have shown a decrease in morning pre-bronchodilator FEV1 not less than 10% and less than or equal to 25% from pre-screening baseline FEV1 at Visit 2.

Exclusion criteria:

  1. Patients with significant pulmonary disease other than asthma or other significant medical conditions (as determined by medical history, examination and clinical investigations at screening)
  2. Patients with a clinically relevant, abnormal screening haematology and/or blood chemistry finding
  3. Patients with a history of upper or lower respiratory tract infection in the past four weeks prior to the pre-screening Visit 1, and during pre-screening and run-in periods
  4. Patients with any exacerbation of their underlying asthma during the eight weeks prior to the pre-screening Visit 1
  5. Patients with active allergic rhinitis requiring treatment with systemic corticosteroids
  6. Any of the following criteria are met during the pre-screening / run-in period (Visits 1 - 6):

    • in clinic pre-bronchodilator forced expiratory volume in one second (FEV1 %) predicted less than 40%,
    • more than 12 puffs rescue salbutamol/albuterol hydrofluoroalkane metered dose inhaler (HFA MDI) per day for > 2 consecutive days,
    • exacerbation of asthma.
  7. Patients with a history of pneumonectomy or who are planning to undergo thoracotomy for any reason
  8. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to the first screening visit 1
  9. Patients with two or more hospitalizations for asthma within the previous twelve months
  10. Patients with a recent history of myocardial infarction during the last twelve months or known coronary heart disease that requires treatment
  11. Patients with a history of hospitalisation due to heart failure in the past twelve months
  12. Patients with myocarditis or any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year
  13. Patients with significant alcohol or drug abuse in the opinion of the investigator within the past two years
  14. Patients with rheumatoid arthritis or other systemic diseases that require immune system modulating treatment
  15. Patients suffering from narrow angle glaucoma with a history of glaucoma, increased intraocular pressure, and/or cataracts
  16. Pregnant or nursing women
  17. Women of childbearing potential not using a highly effective method of birth control.
  18. Patients who have been treated with anti-Immunoglobin-E-antibodies (e.g. omalizumab, Xolair®) or other immune system modulating antibodies such as tumor necrosis factor-alpha blockers within six months prior to Visit 1
  19. Patients who have been treated with the following drugs during the past four weeks prior to Visit 1 or are foreseen to need this during the study:

    • Non-selective beta-blockers (topical cardio-selective beta-blocker eye medications for non-narrow angle glaucoma are allowed),
    • Oral or other systemic corticosteroids,
    • Oral beta-agonists,
    • Changes in allergen desensitisation therapy in last 6 months,
    • Immune system modulating agents such as methotrexate or cyclosporine,
    • Inhibitors of cytochrome P450 3A4 such as antifungals (e.g. ketoconazole, itraconazole), antibiotics (e.g. erythromycin) or antiretroviral drugs.
    • Patients who have been treated with leukotriene modifiers, chromones or theophylline within two weeks prior to Visit 1
    • Patients who have been treated with tiotropium within 3 weeks prior to Visit 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01397201

  Hide Study Locations
Locations
United States, California
1248.6.01047 Boehringer Ingelheim Investigational Site
Fountain Valley, California, United States
1248.6.01023 Boehringer Ingelheim Investigational Site
Fullerton, California, United States
1248.6.01041 Boehringer Ingelheim Investigational Site
Huntington Beach, California, United States
1248.6.01038 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
1248.6.01004 Boehringer Ingelheim Investigational Site
Mission Viejo, California, United States
1248.6.01028 Boehringer Ingelheim Investigational Site
Palmdale, California, United States
1248.6.01044 Boehringer Ingelheim Investigational Site
Stockton, California, United States
1248.6.01034 Boehringer Ingelheim Investigational Site
Walnut Creek, California, United States
United States, Colorado
1248.6.01015 Boehringer Ingelheim Investigational Site
Centennial, Colorado, United States
United States, Florida
1248.6.01035 Boehringer Ingelheim Investigational Site
Aventura, Florida, United States
1248.6.01022 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1248.6.01042 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
United States, Georgia
1248.6.01051 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States
1248.6.01052 Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
United States, Idaho
1248.6.01011 Boehringer Ingelheim Investigational Site
Eagle, Idaho, United States
United States, Illinois
1248.6.01055 Boehringer Ingelheim Investigational Site
Oak Lawn, Illinois, United States
United States, Maryland
1248.6.01019 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
United States, Massachusetts
1248.6.01039 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts, United States
United States, Michigan
1248.6.01037 Boehringer Ingelheim Investigational Site
Ypsilanti, Michigan, United States
United States, Missouri
1248.6.01056 Boehringer Ingelheim Investigational Site
Rolla, Missouri, United States
1248.6.01036 Boehringer Ingelheim Investigational Site
Warrensburg, Missouri, United States
United States, Nebraska
1248.6.01020 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, New Jersey
1248.6.01049 Boehringer Ingelheim Investigational Site
Berlin, New Jersey, United States
1248.6.01054 Boehringer Ingelheim Investigational Site
Trenton, New Jersey, United States
1248.6.01010 Boehringer Ingelheim Investigational Site
Verona, New Jersey, United States
United States, New York
1248.6.01006 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
United States, North Carolina
1248.6.01031 Boehringer Ingelheim Investigational Site
High Point, North Carolina, United States
United States, Ohio
1248.6.01045 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
United States, Oregon
1248.6.01005 Boehringer Ingelheim Investigational Site
Gresham, Oregon, United States
1248.6.01021 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
1248.6.01013 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1248.6.01040 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1248.6.01012 Boehringer Ingelheim Investigational Site
Upland, Pennsylvania, United States
United States, South Carolina
1248.6.01048 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
United States, Texas
1248.6.01050 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1248.6.01002 Boehringer Ingelheim Investigational Site
Live Oak, Texas, United States
1248.6.01046 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1248.6.01001 Boehringer Ingelheim Investigational Site
Waco, Texas, United States
United States, Utah
1248.6.01025 Boehringer Ingelheim Investigational Site
Murray, Utah, United States
United States, Virginia
1248.6.01053 Boehringer Ingelheim Investigational Site
Alexandria, Virginia, United States
United States, Washington
1248.6.01030 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01397201     History of Changes
Other Study ID Numbers: 1248.6, 2010-023168-41
Study First Received: July 18, 2011
Last Updated: April 30, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 15, 2014